# Estrella Immunopharma Inc. (ESLA)

Source: https://www.quantisnow.com/company/ESLA
Generated: 2026-11-10T11:09:43.217Z

- Ticker: ESLA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- SEC CIK: 0001844417

## Latest ESLA news and filings

- 2026-11-04 12:23 UTC [SEC Form 4] [Chief Executive Officer Pussinen Cynthia was granted 1,000,000 stock options (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-pussinen-cynthia-was-granted-1000000-stock-options-6771333)
- 2026-11-03 16:03 UTC [SEC Form 3] [SEC Form 3 filed by new insider Pussinen Cynthia](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-pussinen-cynthia-6769015)
- 2026-10-29 21:28 UTC [SEC Form 8-K] [SEC Form 8-K filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-estrella-immunopharma-inc-6764134)
- 2026-10-26 12:00 UTC [Leadership Update] [Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors](https://www.quantisnow.com/insight/estrella-immunopharma-appoints-cynthia-pussinen-as-chief-executive-officer-and-6757055)
- 2026-10-15 22:45 UTC [Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase](https://www.quantisnow.com/insight/estrella-immunopharma-treats-first-patient-with-two-eb103-infusions-in-6748464)
- 2026-10-14 20:15 UTC [Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma](https://www.quantisnow.com/insight/estrella-immunopharma-activates-intermountain-health-lds-hospital-as-fifth-clinical-6746596)
- 2026-09-08 21:25 UTC [SEC Form 8-K] [Estrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/estrella-immunopharma-inc-filed-sec-form-8-k-notice-of-delisting-6708753)
- 2026-08-26 23:23 UTC [SEC Form 4] [CEO Liu Cheng exercised 100,000 shares at a strike of $0.81, increasing direct ownership by 34% to 397,437 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-liu-cheng-exercised-100000-shares-at-a-strike-of-6696108)
- 2026-08-26 01:55 UTC [SEC Form 4] [Chief Financial Officer Xu Jiandong exercised 100,000 shares at a strike of $0.81, increasing direct ownership by 38% to 365,488 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-xu-jiandong-exercised-100000-shares-at-a-6694783)
- 2026-08-21 21:00 UTC [SEC Form 8-K] [Estrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/estrella-immunopharma-inc-filed-sec-form-8-k-notice-of-delisting-6691645)
- 2026-08-14 14:11 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-estrella-immunopharma-inc-6682232)
- 2026-08-13 21:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-estrella-immunopharma-inc-6681158)
- 2026-08-03 12:00 UTC [Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma](https://www.quantisnow.com/insight/estrella-immunopharma-activates-oregon-health-science-university-as-third-clinical-6658750)
- 2026-07-29 12:00 UTC [Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma](https://www.quantisnow.com/insight/estrella-immunopharma-activates-baylor-scott-white-research-institute-as-second-6652776)
- 2026-07-24 12:00 UTC [Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma](https://www.quantisnow.com/insight/estrella-immunopharma-announces-first-patient-dosed-in-dose-expansion-phase-of-6647922)
- 2026-06-30 21:29 UTC [SEC Form 8-K] [Estrella Immunopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/estrella-immunopharma-inc-filed-sec-form-8-k-submission-of-matters-6621347)
- 2026-05-27 21:25 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-estrella-immunopharma-inc-6575425)
- 2026-05-16 01:26 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-estrella-immunopharma-inc-6558924)
- 2026-05-16 01:24 UTC [SEC Form NT 10-Q filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-estrella-immunopharma-inc-6558922)
- 2026-05-15 15:16 UTC [SEC Form SCHEDULE 13G filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-estrella-immunopharma-inc-6556419)
- 2026-05-05 12:00 UTC [Conference Announcement] [Estrella Immunopharma to Participate in the D. Boral Capital Global Conference](https://www.quantisnow.com/insight/estrella-immunopharma-to-participate-in-the-d-boral-capital-global-6530922)
- 2026-04-30 21:27 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-estrella-immunopharma-inc-6525536)
- 2026-04-30 01:36 UTC [Insider Buy] [Chief Financial Officer Xu Jiandong bought $2,594 worth of shares (2,100 units at $1.24), increasing direct ownership by 0.38% to 265,488 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-xu-jiandong-bought-2594-worth-of-shares-6522225)
- 2026-03-23 12:00 UTC [Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research](https://www.quantisnow.com/insight/estrella-immunopharma-inc-nasdaq-esla-receives-initiating-coverage-with-a-6464298)
- 2026-02-13 22:28 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-estrella-immunopharma-inc-6393276)
- 2026-02-09 12:00 UTC [Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®](https://www.quantisnow.com/insight/estrella-immunopharma-presents-promising-updated-data-on-eb103-in-oral-6380849)
- 2026-02-03 13:00 UTC [Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®](https://www.quantisnow.com/insight/estrella-immunopharma-announces-late-breaking-oral-presentation-of-phase-1-starlight-1-6371295)
- 2026-01-26 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-estrella-immunopharma-inc-6359908)
- 2026-01-22 01:51 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-estrella-immunopharma-inc-6356899)
- 2026-01-16 22:08 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-estrella-immunopharma-inc-6352562)
- 2026-01-13 22:21 UTC [SEC Form 8-K] [Estrella Immunopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/estrella-immunopharma-inc-filed-sec-form-8-k-notice-of-delisting-6348446)
- 2026-01-06 21:01 UTC [SEC Form 8-K] [Estrella Immunopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/estrella-immunopharma-inc-filed-sec-form-8-k-entry-into-a-6338185)
- 2026-01-06 19:02 UTC [Public Offering] [Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement](https://www.quantisnow.com/insight/estrella-immunopharma-announces-closing-of-80-million-registered-direct-offering-6337946)
- 2026-01-06 18:56 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-estrella-immunopharma-inc-6337942)
- 2026-01-05 13:30 UTC [Public Offering] [Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules](https://www.quantisnow.com/insight/estrella-immunopharma-inc-announces-80-million-registered-direct-offering-and-6333332)
- 2025-12-22 15:56 UTC [SEC Form S-1] [SEC Form S-1 filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-estrella-immunopharma-inc-6325024)
- 2025-12-04 14:21 UTC [SEC Form 8-K] [Estrella Immunopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/estrella-immunopharma-inc-filed-sec-form-8-k-other-events-financial-6303197)
- 2025-12-04 13:00 UTC [Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation](https://www.quantisnow.com/insight/estrella-advances-starlight-1-trial-into-phase-ii-following-positive-dsmb-6302905)
- 2025-11-12 21:08 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Estrella Immunopharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-estrella-immunopharma-inc-6274435)
- 2025-11-06 22:17 UTC [SEC Form 8-K] [Estrella Immunopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/estrella-immunopharma-inc-filed-sec-form-8-k-other-events-financial-6266621)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ESLA
- Earnings history: https://www.quantisnow.com/earnings/ESLA
- Dividend history: https://www.quantisnow.com/dividends/ESLA
- Insider transactions: https://www.quantisnow.com/insiders/ESLA
- Options chain: https://www.quantisnow.com/options/ESLA
- SEC 8-K filings only: https://www.quantisnow.com/company/ESLA/8-k
- RSS and alerts for ESLA: https://www.quantisnow.com/docs/rss-feeds.md